AmpC induction by ceftaroline

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 3, 2010, Pages 586-588

  Mushtaq, Shazad ^a   Livermore, David M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

lactamase induction; lactamases; Oxyimino cephalosporins

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE AMPC; CEFOTAXIME; CEFOXITIN; CEFTAROLINE; CEFTRIAXONE; CEPHALOSPORIN; CLOXACILLIN;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CITROBACTER FREUNDII; ENTEROBACTER CLOACAE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; ISOELECTRIC FOCUSING; LETTER; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PROTEUS VULGARIS; PULSED FIELD GEL ELECTROPHORESIS; SERRATIA MARCESCENS; SKIN INFECTION;

BACTERIAL PROTEINS; BETA-LACTAMASES; CEPHALOSPORINS; ENTEROBACTERIACEAE; GENE EXPRESSION REGULATION, BACTERIAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 77950303341     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp493     Document Type: Letter

References (8)

1. Zhanel GG, Sniezek G, Schweizer F et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Drugs 2009; 69: 809-31.
2. Mushtaq S, Warner M, Ge Y et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60:300-11.
3. Eckberg P, Friedland HD, Lee J et al. FOCUS 1 and 2: randomised, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP). In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 2009. Abstract L1-345a. American Society for Microbiology, Washington, DC, USA.
4. Livermore DM. Clinical significance of β-lactamase induction and stable derepression in Gram-negative rods. Eur J Clin Microbiol 1987; 6: 439-45.
5. Cosgrove SE, Kaye KS, Eliopoulous GM et al. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002; 162: 185-90.
6. Kaye KS, Cosgrove S, Harris A et al. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001; 45: 2628-30.
7. Chow JW, Fine MJ, Shlaes DM et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-90.
8. Livermore DM, Mushtaq S, Warner M et al. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases. J Antimicrob Chemother 2008; 62: 1053-6.